Tango Therapeutics (NASDAQ:TNGX) Shares Up 7.5% - Here's What Happened

Key Points

• Tango Therapeutics shares rose 7.5% to $23.69, despite trading volume falling 73% below its average.
• Analyst sentiment remains broadly positive: 14 analysts rate the stock Buy, with a consensus “Moderate Buy” rating and an average price target of $43.46.
• The company missed its latest quarterly EPS estimate, reporting a loss of $0.37 per share versus the expected $0.32 loss; insiders also sold shares recently.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report)'s stock price shot up 7.5% on Monday. The stock traded as high as $23.25 and last traded at $23.69. 909,975 shares were traded during trading, a decline of 73% from the average session volume of 3,409,064 shares. The stock had previously closed at $22.04.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on TNGX shares. JPMorgan Chase & Co. began coverage on Tango Therapeutics in a report on Wednesday, July 15th. They issued an "overweight" rating and a $46.00 price objective on the stock. Weiss Ratings raised shares of Tango Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Wall Street Zen downgraded shares of Tango Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. HC Wainwright increased their target price on shares of Tango Therapeutics from $66.00 to $68.00 and gave the stock a "buy" rating in a research report on Tuesday, August 18th. Finally, Mizuho lifted their price target on shares of Tango Therapeutics from $36.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, July 17th. Fourteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $43.46.

Tango Therapeutics Trading Up 7.6%

The firm's 50-day moving average price is $23.87 and its 200 day moving average price is $25.15. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of -27.75 and a beta of 1.17.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). As a group, equities research analysts anticipate that Tango Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jessica Newcomb sold 8,200 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total value of $198,604.00. Following the completion of the transaction, the insider owned 59,121 shares of the company's stock, valued at approximately $1,431,910.62. This represents a 12.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $24.47, for a total transaction of $660,690.00. Following the sale, the insider directly owned 115,743 shares in the company, valued at $2,832,231.21. This trade represents a 18.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 6.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tango Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Nykredit A S bought a new position in Tango Therapeutics during the 2nd quarter worth approximately $26,000. Allworth Financial LP bought a new stake in shares of Tango Therapeutics in the 2nd quarter valued at $35,000. Global Retirement Partners LLC bought a new stake in shares of Tango Therapeutics in the 2nd quarter valued at $122,000. State of Wyoming acquired a new stake in shares of Tango Therapeutics during the first quarter worth $128,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Tango Therapeutics during the second quarter worth $205,000. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities and activate the immune system against tumors. The company uses functional genomics, including CRISPR-based screening, to identify genetic dependencies that may be selectively targeted in cancer cells while limiting effects on healthy tissue.

Tango's research and development programs include small-molecule therapies and immuno-oncology candidates designed to address genetically defined cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.